All In MedTech

Device Trial Radar · NCT03983512

PULSTA Transcatheter Pulmonary Valve Pre-Approval Study

The PULSTA Transcatheter Pulmonary Valve (TPV) Pre-Approval Study

Last checked: Nov 21, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Oct 7, 2019

Primary completion

Sep 21, 2022

Study completion Dec 2026

Sponsor

Lead sponsor
Taewoong Medical Co., Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Avania
First posted
Jun 12, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and effectiveness of the PULSTA Transcatheter Pulmonary Valve (TPV) System for the treatment of congenital or acquired pulmonary valve stenosis and/or regurgitation who require pulmonary valve replacement.

Conditions

  • Heart Diseases
  • Pulmonary Valve Regurgitation
  • Pulmonary Valve Stenosis
  • Tetralogy of Fallot

Interventions

  • PULSTA TPV SystemDevice

    PULSTA transcatheter pulmonary valve replacement.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Procedural/Device related serious adverse events at 6 monthsTime frame: 6 months

1 more outcomes with a free account

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • Deutsches Herzzentrum Munchen

    München, München, Germany

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.